sacituzumab
gilead sciences
['mbc', 'choice i', ' sg ', 't-dxd', 'bcsm', 'tropics-02']
os from 2nd interim analysis of tropics-02 at #esmo22. median os 14.1 mo w/ sg vs 11.2 mo w/ physicians choice in pts with heavily pretreated hr+/her2- mbc. activity after t-dxd unclear #bcsm 
CME experts Sara Fagerlie, PhD, CHCP & Mindy Tanzola, PhD have joined forces at Front Row to help clinicians & educators manage the oncology information deluge